Otsuka Holdings is often described as a Japanese healthcare group with strong brands, but the economic test for its prescription business is narrower and harder: whether a patient, clinician and payer will keep trusting an expensive medicine course after the first prescription, the first injection, the first blood test, the first prior authorization and the first safety concern.
